arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2004-10-4-197-201arthyper-942Research ArticleСтатьиArticlesОткрытое сравнительное контролируемое исследование применения антагонистов кальция нифедипина SR/GITS и амлодипина у больных гипертонической болезньюOpen comparative controlled study of the use of the calcium antagonists nifedipine SR/GITS and amlodipine in patients with hypertensive diseaseЗвартауН. Э.ZvartauN. E.noemail@neicon.ruРотарьО. П.RotarO. P.noemail@neicon.ruЕмельяновИ. В.YemelyanovI. V.noemail@neicon.ruКонрадиА. О.KonradiA. O.konradi@almazovcentre.ruНИИ кардиологии им. В.А. Алмазова МЗ и СР РФРоссияAlmazov Federal Heart, Blood and Endocrinology CentreRussian Federation200428082004104197201Copyright © Звартау Н.Э., Ротарь О.П., Емельянов И.В., Конради А.О., 20042004Звартау Н.Э., Ротарь О.П., Емельянов И.В., Конради А.О.Zvartau N.E., Rotar O.P., Yemelyanov I.V., Konradi A.O.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/942

Разюме. Проведено сравнительное контролируемое исследование применения антагонистов кальция нифедипина SR/GITS и амлодипина у больных гипертонической болезнью. Результаты свидетельствуют о высоком и стабильном аитигипертоническом эффекте на протяжении суток, безопасности и благоприятном влиянии па качество жизни пациентов нифедипина SR/GITS и амлодипина. Кроме того, на фоне терапии в обеих группах лечения улучшились показатели вариабельности сердечного ритма и суточного профиля артериального давления, являющихся важными факторами риска прогрессирования и смертности от сердечно-сосудистых заболеваний, однако следует отметить, что в группе нифедипина SR/GITS отмечен более выраженный антигипертензивный эфцЧ-кт и более значимое улучшение показателей вариабельности сердечного ритма по сравнению с группой амлодипина.

An open comparative controlled study of the use of the calcium antagonists nifedipine SR/GITS and amlodipine was conducted in patients with hypertensive disease. The results suggest that both drugs have a high and stable antihypertensive activity during a day: they are sale and produce a positive effect on the life quality in the patients. Therapy in both groups improved the parameters of heart rate variability and daily blood pressure profile, which are important risk factors of the progression of cardiovascular diseases and their mortality. However, it should be noted that there was a more marked antihypertensive effect and a more Significant improvement of heart rate variability parameters in the nifedipine SR/GITS group than in the amlodipine group.

артериальная гипертензияантагонисты кальциянифедипин SR/GITSамлодипинarterial hypertensioncalcium antagonistsnifedipine SR/GITSamlodipineReferencesGuidelines Committee. 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-53.Guidelines Committee. 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-53.Furberg C.D. Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality hi patients with coronary heart disease. Circulation 1995: 92: l326 31.Furberg C.D. Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality hi patients with coronary heart disease. Circulation 1995: 92: l326 31.Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double-Blind Treatment with Long-Acting Calcium Channel Blockers or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000, 356: 366-72.Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double-Blind Treatment with Long-Acting Calcium Channel Blockers or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000, 356: 366-72.Major Outcomes High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288; 2981-79.Major Outcomes High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288; 2981-79.Lindholm L.H., Hansson L., Edhom T. et al. Comparison of antihypertensive treatments treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension J. STOP Hypertension J Study Group. J Hypertens 2000 Nov; 18 (11): 1671.Lindholm L.H., Hansson L., Edhom T. et al. Comparison of antihypertensive treatments treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension J. STOP Hypertension J Study Group. J Hypertens 2000 Nov; 18 (11): 1671.Lombardi F., Terranova P. Hypertension and concurrent arrhythmias. Curr Pharm Des 2003; 9 (21): 1703-13.Lombardi F., Terranova P. Hypertension and concurrent arrhythmias. Curr Pharm Des 2003; 9 (21): 1703-13.Weir M.R., Prisant L.M., Papademetrion V. et al. Antihypertensive therapy and quality of life. Influence oj blood pressure reduction, adverse events, and prior antihypertensive therapy Am J Hypertens 1996 Sep: 9 (9): 854-9.Weir M.R., Prisant L.M., Papademetrion V. et al. Antihypertensive therapy and quality of life. Influence oj blood pressure reduction, adverse events, and prior antihypertensive therapy Am J Hypertens 1996 Sep: 9 (9): 854-9.Pickering T., James G. Determinants and consequences of the diurnal rhythm of blood pressure. Am J Hypertens Am J Hypertens 1993: 6 (pl. 2): 1665-95.Pickering T., James G. Determinants and consequences of the diurnal rhythm of blood pressure. Am J Hypertens Am J Hypertens 1993: 6 (pl. 2): 1665-95.Леонова М.В., Демонова А.В., Малышева Е.А., Белоусов Ю.Б. Влияние антагонистов кальция длительного действия на суточный профиль АД у больных с артериальной гипертонией. Рос. кардиол. Журн. 1999; 3: 36-9.Леонова М.В., Демонова А.В., Малышева Е.А., Белоусов Ю.Б. Влияние антагонистов кальция длительного действия на суточный профиль АД у больных с артериальной гипертонией. Рос. кардиол. Журн. 1999; 3: 36-9.Kyngas H., Lahdenpera Т. Compliance оf patients with hypertension and associated factors. J Adv Nurs 1999: 29: 832-9Kyngas H., Lahdenpera Т. Compliance оf patients with hypertension and associated factors. J Adv Nurs 1999: 29: 832-9Ушкалова Е.А. Фармакологические свойства амлодипина-антагониста кальция последнего поколения Фарматека 2004: 14 (91).Ушкалова Е.А. Фармакологические свойства амлодипина-антагониста кальция последнего поколения Фарматека 2004: 14 (91).Gong L., Zhang W.,. Zhu Y. et al. Shanghai Trial of Nifidepine in the Elderly (STONE). J Hypertens 1996: 14: 1237-45.Gong L., Zhang W.,. Zhu Y. et al. Shanghai Trial of Nifidepine in the Elderly (STONE). J Hypertens 1996: 14: 1237-45.Radaelli A., Bernardi L., Valle F., Leuzzi S. et al. Cardiovascular autonomic modulation in essential hypertension: effect of tilting. Hypertension 1994: 24. 556-63.Radaelli A., Bernardi L., Valle F., Leuzzi S. et al. Cardiovascular autonomic modulation in essential hypertension: effect of tilting. Hypertension 1994: 24. 556-63.Chakko S., Mulingtopang R.F. Huikuri H.V. et al. Alternations in heart rate variability audits arcadian rhythm in hypertensive patients with left ventricular hypertrophy free of coronary artery disease. Am Heart J 1993: 126; 1364-72.Chakko S., Mulingtopang R.F. Huikuri H.V. et al. Alternations in heart rate variability audits arcadian rhythm in hypertensive patients with left ventricular hypertrophy free of coronary artery disease. Am Heart J 1993: 126; 1364-72.Langewitz W., Ruddel H., Schacbinger H. Reduced parasympathetic cardiac control in patients with hypertension at rest and under mental stress. Am Heart J 1994; 127: 122-8.Langewitz W., Ruddel H., Schacbinger H. Reduced parasympathetic cardiac control in patients with hypertension at rest and under mental stress. Am Heart J 1994; 127: 122-8.Omvik P., Thaulow E., Herland O.B. et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens 1993 Jan; 11 (1): 103-13.Omvik P., Thaulow E., Herland O.B. et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens 1993 Jan; 11 (1): 103-13.Фомина И.Г. Новая форма нифедипина (нифекард XL) в лечении артериальной гипертонии. Клин. фармакол. и тер. 2003; 3.Фомина И.Г. Новая форма нифедипина (нифекард XL) в лечении артериальной гипертонии. Клин. фармакол. и тер. 2003; 3.

The authors declare that there are no conflicts of interest present.